Chemotherapy Utilized in Pretreated Metastatic Castration-Resistant Prostate Cancer
This roundtable series discusses when to use chemotherapy and best dosing practices in patients with metastatic castration-resistant prostate cancer after treatment with docetaxel, as discussed by participants at virtual live events.
CARD Trial Shows Survival and QOL Benefits of Cabazitaxel in mCRPC
June 15th 2022During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC
July 5th 2022During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
Discussing the Role of Cabazitaxel Post–Hormone Therapy for mCRPC
November 30th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
Considerations on Tolerability of Cabazitaxel in mCRPC
December 16th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants their experiences with using cabazitaxel in patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
